You have no items in your cart.
Lung Function Reduced in LOPD Despite Long-term Myozyme Use
Pompe Disease News
Despite treatment for years with Myozyme (alglucosidase alfa) — marketed in the U.S. as Lumizyme — people with late-onset Pompe disease (LOPD) still develop airway abnormalities and experience reduced lung function, ... Read more